Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

Abstract

Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with other treatment responses (p < 0.0001).